Industry Daily Summary
Industry Daily Summary: What Happened on November 16, 2026
J&J agrees to buy Ollin for up to $3.3 billion
Lilly agreed to buy Calytrix for up to $1.5 billion. Novartis and Sanofi also signed research deals.
Today in brief
Johnson & Johnson agreed to acquire Ollin Biosciences for $2.2 billion upfront, plus up to $1.125 billion in milestones.12 The deal brings OLN324, an antibody in Phase 3 development for eye disease, and up to $750 million in development funding from Blackstone Life Sciences.12
Lilly will acquire Calytrix Bio for up to $1.5 billion, adding a preclinical antibody program for rare blood disorders.34 Novartis licensed OBI Pharma’s platform for cancer antibody-drug conjugates, and Sanofi struck a research and licensing agreement with Seawolf Therapeutics.3
J&J will pay $2.2 billion upfront for Ollin
Johnson & Johnson agreed to acquire Ollin Biosciences for $2.2 billion upfront, with up to $1.125 billion more tied to regulatory and commercial milestones.12 Ollin’s lead program, OLN324, is a bispecific antibody in Phase 3 development for wet age-related macular degeneration and diabetic macular edema.12
OLN324 targets VEGF and Ang2, pathways involved in retinal disease that Roche’s Vabysmo also targets.12 Ollin said a Phase 1b head-to-head study found greater structural changes and numerically greater vision improvement with OLN324 than with Vabysmo.2 In another reported comparison, 82% of participants on a 4 mg dose went 12 weeks without retreatment, versus 81% on faricimab.3
J&J will lead the pivotal trials, while Blackstone Life Sciences agreed to fund up to $750 million for late-stage development.24 The acquisition also includes OLN102, an investigational antibody for thyroid eye disorder.2 The companies expect the deal to close before the end of 2026, subject to regulatory approvals and customary conditions.34
Lilly adds Calytrix’s preclinical blood-disorder program
Lilly agreed to buy Calytrix Bio in a cash deal worth up to $1.5 billion. The total includes an upfront payment whose amount wasn’t disclosed, plus clinical and regulatory milestones.34 Calytrix’s lead program is a preclinical antibody targeting mutant calreticulin in essential thrombocythemia and myelofibrosis.34
Calytrix says the target could let the antibody remove disease-driving cells while preserving healthy blood-cell production.3 One account counted the deal as Lilly’s 15th announced acquisition of 2026. Another counted 14.35
Novartis and Sanofi sign research partnerships
Novartis signed a collaboration and license agreement with OBI Pharma to develop next-generation antibody-drug conjugates using OBI’s platform.3 OBI will receive $30 million upfront, with possible milestone payments and tiered royalties. Novartis gets worldwide rights to selected payload classes and an option to add others.3
Seawolf Therapeutics raised $100 million in seed and Series A funding and signed a research collaboration and exclusive license agreement with Sanofi.3 The agreement covers bleeding disorders and undisclosed indications, with potential milestone payments of up to $1.2 billion plus tiered royalties.3
Seawolf says its DNA-delivery platform could produce proteins longer than RNA-based lipid nanoparticles and allow redosing, unlike viral gene therapies.3
Also worth knowing
-
Medtronic plans to buy Contego Medical for $380 million to expand its offerings for carotid artery and peripheral vascular disease.6
-
Revolution Medicines CEO Mark Goldsmith said the US launch of Rasonque is advancing quickly but is complicated by expanded access, which provided the drug to more than 2,000 patients.7
-
TRIMTECH and Biogen signed a protein-degrader research and licensing-option deal worth up to $411 million plus royalties, including up to $32 million in upfront and research payments.8
-
P
AmyriAD Therapeutics acquired worldwide rights to AD04, a mild Alzheimer’s disease program described as ready for Phase 2b development.4
Also published
- Executive Conversations: What Sets Strategic Trade Teams Apart? Pharmaceutical Commerce
- The Adaptive HCP Engagement Playbook Fierce Biotech
- J&J bets $2.2B on Ollin’s vision loss drug BioPharma Dive
- STAT+: Biotech’s rebound isn’t lifting all boats equally STAT Biotech
- J&J cuts $3.3bn deal to buy eye drug developer Ollin pharmaphorum
- China’s pharma industry wants to go global. The US could get in its way. PharmaVoice
- Lilly strikes again, buying Calytrix in $1.5bn deal pharmaphorum
- An AAPS PharmSci 360 overview: Making better decisions faster, earlier, with fewer resources pharmaphorum
- Q3 2026 Earnings Review Matt Gamber
- China overtakes Europe in healthcare investing sentiment pharmaphorum
- BeOne, Hengrui top list of China’s most powerful drugmakers STAT Biotech
- Notable TechBio startups and companies operating in India 🇮🇳 (II) MetaphysicalCells
- From Hong Kong to Düsseldorf: HKSTP Makes MEDICA Debut with Breakthrough MedTech Ventures Clinical Trials Arena
- ASHG Notes: TTP plc's Lysate-to-Library Prototype Omics! Omics!